Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -5.63%12 Equity-to-Asset is 0.94 as of Jun. 2026. GuruFocus rates AVLN with a GF Score™ of 12/100. Among 1,412 Biotechnology companies, Avalyn Pharma ranks better than 92.21% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Avalyn Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $398.35 Mil. Avalyn Pharma's Total Assets for the quarter that ended in Jun. 2026 was $425.45 Mil.
The historical rank and industry rank for Avalyn Pharma's Equity-to-Asset or its related term are showing as below:
AVLN'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.95 Med: -1.5 Max: 0.94
Current: 0.94
During the past 2 years, the highest Equity to Asset Ratio of Avalyn Pharma was 0.94. The lowest was -1.95. And the median was -1.50.
AVLN's Equity-to-Asset is ranked better than 92.21% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs AVLN: 0.94
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Avalyn Pharma Equity-to-Asset Related Terms
Avalyn Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Avalyn Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma Equity-to-Asset Chart
Avalyn Pharma Annual Data
Trend
Dec24
Dec25
Equity-to-Asset
0.93
0.90
Avalyn Pharma Quarterly Data
Mar25
Jun25
Mar26
Jun26
Equity-to-Asset
-
-
0.80
0.94
AVLN vs LBRX, LTGO, NVAX: Equity-to-Asset Comparison
For the Biotechnology subindustry, Avalyn Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Avalyn Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma (AVLN) has a Equity-to-Asset of 0.94 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #110 out of 1412 companies in the Biotechnology industry, placing it in the top 7.8%.
Is Avalyn Pharma's Equity-to-Asset too high?
Avalyn Pharma's current Equity-to-Asset is 0.94. The Biotechnology industry median Equity-to-Asset is 0.69. Avalyn Pharma's value of 0.94 is 36.2% above this industry median. Based on the distribution chart, Avalyn Pharma ranks #110 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalyn Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Equity-to-Asset compare to LBRX and LTGO?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #110 out of 1412 companies for Equity-to-Asset. This places Avalyn Pharma in the top 8% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.69. Avalyn Pharma's value of 0.94 is 36.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avalyn Pharma's current Equity-to-Asset of 0.94 is 36.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avalyn Pharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current Equity-to-Asset is 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Equity-to-Asset of 0.94. The current Equity-to-Asset is 0.94 and 36.2% above the Biotechnology industry median of 0.69. Avalyn Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Equity-to-Asset is 0.94 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
12GF Score
Get the complete analysis for AVLN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
